Abstract
Introduction
The aim of this work is to evaluate treatment persistence and clinical outcomes after 6 months of on-label guselkumab use in patients with rheumatologist-diagnosed active psoriatic arthritis (PsA) enrolled in the CorEvitas PsA/Spondyloarthritis Registry.
Methods
Participants with PsA who initiated and persisted with on-label guselkumab use post-Food and Drug Administration (FDA) approval for active PsA (7/13/2020; subcutaneous 100 mg at weeks 0, 4, and every 8 weeks) at their 6-month follow-up visit (occurring through 3/31/2023) comprised the primary analysis population (On-Label Persisters). Hierarchical, multiplicity-controlled primary and secondary outcomes were mean (95% confidence interval) changes from baseline at 6 months in clinical Disease Activity Index for PsA (cDAPSA; primary), Physician Global Assessment (PGA) of arthritis and psoriasis (visual analog scale [VAS] 0–100), patient-reported pain (VAS 0–100), and percent body surface area with psoriasis (%BSA). Paired t tests determined changes that were statistically significantly different from 0 (α = 0.05).
Results
Among 114 patients who initiated on-label guselkumab and had eligible baseline and 6-month visits, 90 (78.9%) had persistent use. Among these On-Label Persisters at baseline, mean duration of PsA symptoms = 13.6 years; mean cDAPSA, PGA, and patient-reported pain = 22.0, 42.3, and 57.0, respectively; 94.4% had a history of psoriasis (mean BSA 7.6%); and 18.9% and 73.3%, respectively, previously received 1 or ≥ 2 biologic/targeted synthetic disease-modifying antirheumatic drugs. The mean change (improvement) in cDAPSA was − 5.4 (− 8.5, − 2.3; p < 0.001) at 6 months. Significant mean improvements in PGA (− 19.0 [− 24.2, − 13.8]), patient-reported pain (− 9.1 [− 14.4, − 3.8]), and %BSA (− 5.1 [− 7.6, − 2.7]) were also observed (all p < 0.001).
Conclusions
In this real-world PsA population, generally characterized by longstanding, treatment-resistant, active disease at baseline, persistent guselkumab use in nearly 80% of patients with on-label use was accompanied by significant improvements in joint and skin symptoms and patient-reported pain at 6 months. These registry data support results from randomized clinical trials demonstrating the efficacy of guselkumab in improving PsA signs and symptoms.
Trial Registration
clinicaltrials.gov: NCT02530268.
Graphic abstract
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Why carry out this study? |
Guselkumab, a fully human, selective, interleukin-23p19-subunit inhibitor, demonstrated significant efficacy in reducing the signs and symptoms of psoriatic arthritis (PsA) in phase 3 studies and was approved by the Food and Drug Administration July 13, 2020 for adults with active PsA. |
Real-world data on the effectiveness of guselkumab in adults with active PsA are currently limited. |
We evaluated the effectiveness of guselkumab in a real-world setting utilizing data from a cohort of adults with active PsA from the CorEvitas PsA/Spondyloarthritis Registry, who had persistent on-label guselkumab use at their 6-month follow-up visit. |
What was learned from the study? |
In this real-world PsA population, generally characterized by longstanding, treatment-resistant, active disease at baseline, nearly 80% of patients who initiated treatment with on-label guselkumab had persistent use at the 6-month follow-up visit. |
Significant improvements in PsA peripheral joint and skin disease and patient-reported pain were observed in patients with 6 months of persistent on-label guselkumab use. |
The findings from this analysis offer valuable insights on the effectiveness of guselkumab in treating adults with active PsA seen in routine clinical practice in the United States. |
Digital Features
This article is published with digital features, including a graphical abstract, to facilitate understanding of the article. To view digital features for this article go to: https://doi.org/10.6084/m9.figshare.23748942.
Introduction
Approximately 30% of the more than 7.5 million adults in the United States (US) with psoriasis develop psoriatic arthritis (PsA), [1] a chronic inflammatory disease that is characterized by involvement across distinct domains, including peripheral arthritis, axial disease, enthesitis, dactylitis, and skin and nail psoriasis [2,3,4]. Uncontrolled active PsA has been associated with profound functional disability, diminished quality of life, and accelerated mortality [2,3,4].
The heterogeneous nature of PsA necessitates treatment individualized by symptom severity, clinical manifestations, and comorbidities [3,4,5,6]. Treatment recommendations include nonpharmacologic therapies and conventional synthetic (cs), targeted synthetic (ts), or biologic (b) disease-modifying antirheumatic drugs (DMARDs) [4, 5, 7]. In the 2021 update of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis treatment recommendations, the use of biologics, including selective interleukin-23 inhibitors, was strongly recommended to treat various PsA manifestations, such as peripheral arthritis (regardless of prior csDMARD use), enthesitis, dactylitis, and skin and nail psoriasis [4].
Guselkumab, a fully human interleukin-23p19-subunit inhibitor, was approved by the US Food and Drug Administration (FDA) to treat moderate-to-severe plaque psoriasis in July 2017 and to treat active PsA on July 13, 2020 [8, 9]. In the pivotal, phase 3, placebo-controlled DISCOVER-1 [10] and DISCOVER-2 [11] PsA trials, guselkumab demonstrated significant efficacy across joint, skin, and health-related quality of life outcomes and exhibited a positive benefit–risk profile among both biologic-naïve and tumor necrosis factor inhibitor (TNFi)-experienced individuals with active PsA. Findings from the subsequent Phase 3b COSMOS trial further demonstrated guselkumab efficacy and safety in patients with active PsA and inadequate response to TNFi (TNFi-IR) [12].
Given the relatively recent approval of guselkumab for treating active PsA, real-world data on its effectiveness in this population are limited. We previously described the characteristics of a cohort of patients with rheumatologist-diagnosed, active PsA in the US-based CorEvitas PsA/Spondyloarthritis (SpA) Registry who initiated guselkumab [13]. At guselkumab initiation, these registry participants had active peripheral joint and skin disease and reported substantial pain; a considerable proportion also had axial involvement. The current study evaluated guselkumab real-world effectiveness utilizing data from patients with PsA in the CorEvitas PsA/SpA Registry who initiated guselkumab treatment and had an eligible 6-month follow-up visit. Herein, we report changes in key clinical disease activity outcomes among registry participants who initiated on-label guselkumab treatment and had persistent use through the 6-month follow-up visit.
Methods
Data Source
The CorEvitas PsA/SpA Registry, initiated in 2013, is a US, prospective, multicenter, observational registry of patients with PsA or SpA under the care of rheumatologists. Registry enrollment criteria were previously reported [13] and are detailed in Supplementary Material Table 1. The registry collects data from rheumatologists practicing in private or academic settings and from patients during their clinical visits. At enrollment, a patient’s medical history, including prior and current PsA treatment, is captured from medical records. Longitudinal data are collected from patients and their treating rheumatologist during routine follow-up visits occurring approximately every 6 months (180 days from the last registry visit within a window of − 30 to + 90 days).
As of March 31, 2023, the registry included 68 private and academic clinical sites with 76 rheumatologists throughout 30 states and had enrolled 5996 patients, of whom 4969 (82.9%) had PsA. The registry dataset utilized for the current analyses includes these 4969 participating patients with PsA, representing 13,530.6 patient-years of follow-up and mean/median follow-up times since enrollment of 3.6/2.9 years, respectively.
This study was performed in accordance with the Declaration of Helsinki and the Guidelines for Good Pharmacoepidemiology Practice. All participating investigators were required to obtain full governing board approval for conducting noninterventional research involving humans with a limited dataset. Sponsor approval and continuing review were obtained through a central Institutional Review Board (IRB), the New England Independent Review Board (no. 120160939). For academic investigative sites that did not receive authorization to use the central IRB, full board approval was obtained from their respective governing IRBs, and documentation of approval was submitted to CorEvitas, LLC (Waltham, MA, USA) before the site’s participation and initiation of any study procedures. All patients provided written informed consent and authorization before participating.
Assessments The baseline visit was defined as the CorEvitas PsA/SpA Registry visit associated with guselkumab initiation. For patients who initiated guselkumab during a clinical visit, that visit was considered the baseline visit. For patients who initiated guselkumab between clinical visits, the prior visit was considered the baseline visit if it occurred ≤ 4 months before initiation. If the prior visit occurred > 4 months before guselkumab initiation, the first subsequent visit after initiation was considered the baseline visit if it occurred ≤ 1 month after therapy start. Otherwise, patients were excluded from this analysis. The 6-month follow-up visit was the registry visit within a 5- to 9–month window after guselkumab initiation.
For these analyses, PsA clinical features evaluated included times since PsA symptom onset and diagnosis, tender (TJC; 0–68) and swollen (SJC; 0–66) joint counts, PGA of arthritis (visual analog scale [VAS] 0–100) [14, 15], PGA of arthritis and psoriasis (VAS 0–100) [14], patient-reported pain (VAS 0–100; minimally important improvement defined as 10 points [16]), dactylitis count (0–20) [17], Leeds Enthesitis Index (LEI; 0–6) [18], and Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index (0–16) [19]. Psoriasis assessments included psoriasis diagnosis, percent body surface area with psoriasis (%BSA), and Investigator’s Global Assessment (IGA; 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, 4 = severe) of psoriasis [20] among patients with a history of psoriasis (prior or current), as well as nail psoriasis VAS (0–100) among patients with nail involvement. The presence of axial involvement (axial PsA) was determined by the physician using criteria detailed in Supplementary Material Table 2.
Composite measures of disease activity included the clinical Disease Activity Index for PsA (cDAPSA), the Clinical Disease Activity Index (CDAI), and the modified Routine Assessment of Patient Index Data 3 (RAPID3). A cDAPSA score (calculated using 0–68 TJC, 0–66 SJC, patient global assessment [PtGA] of arthritis [0–10], and patient-reported pain [0–10]) ≤ 4 indicates remission, and scores > 4 to ≤ 13, > 13 to ≤ 27, and > 27 indicate low, moderate, and high disease activity, respectively [21]. A CDAI score (calculated based on 0–28 TJC, 0–28 SJC, PtGA of arthritis [0–10], and PGA of arthritis [0–10]) ≤ 2.8 indicates remission and scores > 2.8 to ≤ 10, > 10 to ≤ 22, and > 22 indicate low, moderate, and high disease activity, respectively [22]. The modified RAPID3 is derived from the Modified Multidimensional Health Assessment Questionnaire, PtGA of arthritis (0–10), and patient-reported pain (0–10) [23, 24].
Achievement of minimal disease activity (MDA) or very low disease activity (VLDA) disease states required meeting ≥ 5 or all 7, respectively, of the following criteria: TJC ≤ 1, SJC ≤ 1, BSA with psoriasis ≤ 3%, patient-reported pain (0–100) ≤ 15, PtGA of arthritis and psoriasis (0–100) ≤ 20, Health Assessment Questionnaire-Disability Index [25] ≤ 0.5, and tender entheseal points ≤ 1 [26]. Supplementary Material Table 2 provides additional details on outcomes.
Statistical Analyses
Analysis populations The study population included registry participants who initiated guselkumab on or after October 20, 2018 and had a 6-month follow-up visit on or before March 31, 2023. The primary analysis population was defined as patients who received the FDA-approved guselkumab dosing regimen for patients with active PsA (i.e., after July 13, 2020; 100 mg administered subcutaneously at weeks 0, 4, and every 8 weeks thereafter [8]) and persisted with this dosing regimen through the 6-month visit (On-Label Persisters). To support the reliability and generalizability of findings, a sensitivity analysis was conducted in a cohort of All Persisters, defined as all patients who initiated guselkumab, regardless of date or dosing regimen, and had persistent use reported at the 6-month visit.
Primary, secondary, and exploratory outcomes The primary outcome was mean (95% confidence interval [CI]) change in cDAPSA score from baseline at 6 months. Secondary outcomes (in order of multiplicity-controlled testing) were change from baseline at 6 months in PGA of arthritis and psoriasis, patient-reported pain, and %BSA among patients with a history of psoriasis (prior or current) at baseline.
Prespecified exploratory outcomes were mean change from baseline at 6 months in CDAI, modified RAPID3, and PGA of arthritis scores among all patients, and in nail psoriasis VAS score, dactylitis count, LEI score, and SPARCC Enthesitis Index score among patients with respective baseline scores > 0. Additional outcomes at 6 months included achievement of: cDAPSA or CDAI low disease activity (LDA)/remission among patients with cDAPSA or CDAI moderate-to-high disease activity, respectively, at baseline; IGA 0/1 among patients with a score ≥ 2 at baseline; IGA 0 among patients with a score ≥ 1 at baseline; MDA/VLDA response among patients not in MDA/VLDA at baseline; and < 3% BSA among patients with ≥ 3% BSA affected at baseline.
Data analyses Patient characteristics at baseline and clinical features and outcomes at baseline and 6 months were summarized using means and standard deviations (SDs) and/or medians and interquartile ranges for continuous variables and numbers and proportions of patients for categorical or ordinal variables. Clinical features, outcomes at 6 months, and mean (95% CI) changes from baseline at 6 months in continuous clinical features and outcomes were determined among patients with evaluable data at both timepoints. Paired t tests determined whether changes in continuous outcomes from baseline at 6 months were statistically significantly different from 0 (α = 0.05). Generalized McNemar testing was utilized for categorical outcomes; a single proportion, one-sided test was used to calculate p values testing the null hypothesis that the proportion of patients achieving response at 6 months is equal to 0%. Data analyses were performed using Stata 16 (College Station, TX, USA).
A fixed-sequence statistical strategy was employed to control for multiplicity, whereby the primary and secondary outcomes were tested in a predefined order, each at α = 0.05, moving within each outcome family (primary and secondary) to a subsequent outcome only after success (p < 0.05) of the previous outcome. After evaluation of the primary outcome (cDAPSA), PGA of arthritis and psoriasis, patient-reported pain, and %BSA were tested in sequence. All further exploratory outcomes were evaluated in random order without multiplicity controls. As such, the unadjusted (nominal) p values reported for such outcomes should be interpreted as supportive only.
Results
Patient disposition
Of the 329 patients with PsA enrolled in the CorEvitas PsA/SpA Registry who initiated guselkumab at or after enrollment, 133 had eligible baseline and 6-month follow-up visits as of March 31, 2023 (All Initiators) (Fig. 1), while 196 did not. Of the 133 All Initiators, 104 (78.2%) had persistent guselkumab use at 6 months (All Persisters). Among the 29 patients who discontinued guselkumab before the 6-month visit (Non-Persisters), three had a reduction in therapy (discontinued guselkumab in combination with another therapy and continued the alternate monotherapy), eight stopped therapy, and 18 switched from guselkumab to another therapy. Reasons provided by treating rheumatologists for discontinuation of guselkumab therapy included inadequate initial response (n = 10), failure to maintain initial response (n = 4), and minor side effect (n = 3) (Fig. 1).
Of the 133 All Initiators, 114 received guselkumab on-label (after FDA approval for active PsA and at the approved dosing regimen). In this subset of 114 On-Label Initiators, 90 (78.9%) had persistent guselkumab use at 6 months (On-Label Persisters; Fig. 1). The majority of On-Label Persisters (82/90; 91.1%) initiated guselkumab at their baseline visit, while 8.9% (8/90) initiated guselkumab between visits and had a baseline visit within 4 months prior to through 1 month after initiation. Of the remaining 19 All Initiators, three started guselkumab after FDA approval for psoriasis but prior to approval for PsA, four received a non-FDA-approved guselkumab dosing regimen (100-mg dose every 13 weeks), and 12 did not have sufficient information available to determine the dosing regimen received.
Patient demographics and clinical characteristics
Among the 90 On-Label Persisters comprising the primary analysis cohort, mean (SD) age at baseline was 55.2 (12.5) years; the majority were female (69.7%), White (91.1%), and had a body mass index ≥ 30 kg/m2 (63.6%). The most prevalent comorbidities were hypertension (32.2%), fibromyalgia (23.3%), depression (22.2%), and diabetes (20.0%). Three patients had related conditions of inflammatory bowel disease (IBD, i.e., Crohn’s disease, ulcerative colitis, possible IBD, and/or other IBD), and one had uveitis (Table 1).
At baseline, on average, patients had longstanding, treatment-resistant disease that was active across PsA domains (Table 1). Among On-label Persisters, mean (SD) durations since PsA symptom onset and diagnosis were 13.6 (11.2) and 8.9 (7.9) years, respectively. Most (92.2%) patients were b/tsDMARD-experienced, with 18.9 and 73.3% having previously received one or at least two b/tsDMARDs, respectively, and 73.3, 70.0, and 44.4% having previously received at least one TNFi, non-TNFi bDMARD, or tsDMARD, respectively (Table 2).
Despite prior use of multiple advanced therapies by most On-label Persisters, moderate overall disease activity was observed at baseline, as indicated by mean (SD) cDAPSA and CDAI scores of 22.0 (15.1) and 15.8 (9.8), respectively, as well as 71.8 and 67.1% of patients, respectively, exhibiting cDAPSA and CDAI moderate-to-high disease activity (Table 3). Consistently, guselkumab was initiated due to active disease in 83.3% of these patients (reasons for initiating guselkumab and discontinuing prior therapy are summarized in Table 2). In total, 70.0% of patients received guselkumab as monotherapy.
Regarding specific disease domains, 85.1% (74/87) and 47.1% (41/87) of patients had actively tender (mean [SD] 10.2 [12.1]) and swollen (5.0 [4.5]) joints at baseline; mean (SD) PGA of arthritis and psoriasis and patient-reported pain scores were 42.3 (23.7) and 57.0 (24.6), respectively. Twelve (13.3%) patients had a dactylitis count > 0 (mean [SD] 2.6 [1.8]). An LEI or SPARCC Enthesitis Index score > 0 was reported for 25 (28.7%) and 33 (36.7%) patients, respectively, with respective mean (SD) scores of 2.3 (1.4) and 3.5 (2.9). Axial PsA was identified in 40.0% of patients. Among On-Label Persisters with prior or current psoriasis, 49.4% (42/85) had ≥ 3% BSA affected by psoriasis, with a mean of 14.5% BSA affected. Additionally, among patients with prior or current psoriasis, 63.1% (53/84) had an IGA score ≥2 (representing mild-to-severe skin disease) and 41.2% (35/85) had a nail psoriasis VAS score > 0 (mean [SD] 19.9 [17.8]) (Table 1).
Patient demographics and clinical characteristics of All Persisters were generally consistent with those of On-Label Persisters (Tables 1, 2, and 3). Relative to All Persisters, Non-Persisters had a higher prevalence of axial involvement and history of fibromyalgia, a lower mean TJC, a lower proportion of patients with private healthcare insurance, shorter mean duration of most recent prior PsA therapy, and less extensive nail psoriasis at baseline (Supplementary Material Table 3).
Primary analysis of effectiveness—On-Label Persisters
Among On-Label Persisters, the mean cDAPSA score was significantly decreased from 21.6 at baseline to 16.1 at 6 months (mean change [95% CI]: − 5.4 [− 8.5, − 2.3]; p < 0.001) (Fig. 2A). Significant mean improvements in PGA of arthritis and psoriasis (− 19.0 [− 24.2, − 13.8]; p < 0.001), patient-reported pain (− 9.1 [− 14.4, − 3.8]; p < 0.001), and %BSA (− 5.1 [− 7.6, − 2.7]; p < 0.001) were observed at 6 months (Fig. 2A).
Prespecified exploratory outcomes also improved from baseline at 6 months in the primary analysis of On-Label Persisters (Table 4). Mean (95% CI) improvement in PGA of arthritis was − 15.4 (− 19.9, − 10.8; nominal p < 0.001). Overall disease activity improvement was also demonstrated by mean (95% CI) decreases in CDAI (− 4.3 [− 6.7, − 2.0; nominal p < 0.001]) and modified RAPID3 (− 0.6 [− 0.9, − 0.3; nominal p < 0.001]) scores. Among patients with enthesitis at baseline, mean (95% CI) change was − 1.6 (− 2.2, − 1.0; nominal p < 0.001) for LEI and − 1.9 (− 3.1, − 0.7; nominal p = 0.002) for SPARCC Enthesitis Index scores. Of the 12 patients with a dactylitis count > 0 at baseline, six achieved resolution by 6 months (data not shown), with a mean (95% CI) change of − 1.5 (− 3.8, 0.8; nominal p = 0.17). Mean (95% CI) reduction in nail psoriasis VAS score among patients with a score > 0 at baseline was − 11.0 (− 17.6, − 4.4; nominal p = 0.002).
Additionally, among patients with cDAPSA or CDAI moderate-to-high disease activity at baseline, 25.0% (13/52; 95% CI: 14.0%, 38.9%) achieved cDAPSA LDA/remission and 32.0% (16/50; 95% CI: 19.5%, 46.7%) achieved CDAI LDA/remission, respectively, at 6 months. An IGA 0/1 score was achieved at 6 months by 51.0% (26/51; 95% CI: 36.6%, 65.2%) of patients with a score ≥ 2 at baseline, IGA 0 score was achieved by 29.5% (18/61; 95% CI: 18.5%, 42.6%) of patients with a score ≥ 1 at baseline, and BSA with psoriasis < 3% was achieved by 58.5% (24/41; 95% CI: 42.1%, 73.7%) of patients with ≥ 3% BSA affected at baseline (Fig. 3). Mean changes in %BSA affected by psoriasis were − 6.6 (95% CI: − 9.6, − 3.7) in the 63 patients with > 0 BSA affected at baseline and − 10.0 (95% CI: − 14.3, − 5.8) in 41 patients with ≥ 3% BSA affected at baseline. Among patients not in MDA/VLDA at baseline, 21.5% (14/65; 95% CI: 12.3%, 33.5%) achieved MDA/VDLA at 6 months (Fig. 3).
Sensitivity analysis of effectiveness—All Persisters
Consistent with effectiveness observed in On-Label Persisters, mean (95% CI) improvements were observed in All Persisters for cDAPSA (− 4.9 [− 7.6, − 2.1; nominal p < 0.001]), PGA of arthritis and psoriasis (− 17.0 [− 21.8, − 12.2; nominal p < 0.001]), patient-reported pain (− 7.6 [− 12.6, − 2.6; nominal p = 0.004]), and %BSA (− 4.8 [− 7.1, − 2.5; nominal p < 0.001]) (Fig. 2B). Overall disease activity improved, as demonstrated by mean (95% CI) decreases in composite disease activity scores (CDAI: − 3.9 [− 6.0, − 1.8], nominal p < 0.001 and modified RAPID3: − 0.5 [− 0.8, − 0.2], nominal p = 0.002) (Table 4). Improvements in PGA of arthritis, dactylitis, and enthesitis (Table 4), as well as the proportions of All Persisters achieving cDAPSA and CDAI LDA, IGA 0/1, IGA 0, < 3% BSA, and MDA/VLDA, at 6 months were comparable to those in the On-Label Persisters (Fig. 3).
Discussion
In a previous report characterizing patients with PsA in the CorEvitas PsA/SpA Registry, a cohort of patients who initiated guselkumab for PsA was observed to have active peripheral joint and skin disease and substantial pain [13]. Here we describe real-world effectiveness of guselkumab in a cohort of registry participants who initiated on-label guselkumab treatment and had persistent use at their 6-month follow-up visit, a population generally characterized by longstanding, treatment-resistant, active PsA at the time of guselkumab initiation.
Among On-Label Initiators with a 6-month follow-up visit, nearly 80% continued treatment through the 6-month visit. This finding is consistent with the high retention rates of guselkumab-randomized patients in the phase 3, placebo-controlled trials of guselkumab in patients with active PsA, including TNFi-IR patients, through 1 year of DISCOVER-1 (94%) [27] and COSMOS (88%) [12] and through 2 years of DISCOVER-2 (90%) [28, 29]. High guselkumab persistence at 2 years (84%) was also observed in a retrospective study conducted in Spain evaluating 90 patients who initiated guselkumab for PsA or psoriasis in clinical practice [30]. In a more limited real-world observational Italian cohort of 24 patients with early PsA and extensive skin involvement who initiated guselkumab, more than two-thirds continued treatment through 1 year [31]. Furthermore, among patients with psoriasis, including those with concurrent PsA, enrolled in the British Association of Dermatologists Biologic and Immunomodulators Register, guselkumab had the highest drug survival that was associated with effectiveness over 2 years of the biologics evaluated [32]. Consistently, in a recent claims database analysis of biologic-naïve and biologic-experienced patients with psoriasis who initiated treatment with guselkumab, adalimumab, secukinumab, or ixekizumab, persistence over 24 months was highest for those receiving guselkumab [33].
In the current analysis of patients with persistent on-label guselkumab use, 92% previously received at least one b/tsDMARD at baseline. Seventy percent of patients received guselkumab as monotherapy. Most (93%) patients in the Spanish cohort who received guselkumab for PsA or psoriasis in clinical practice were also biologic-experienced [30]. Of note, clinical response rates in the DISCOVER and COSMOS trials were generally consistent between patients who received guselkumab as monotherapy (37–47%) and those reporting concomitant methotrexate use (53–63%) [10,11,12].
On average, our study cohort of On-Label Persisters exhibited active PsA across multiple domains at baseline, as demonstrated by assessments of peripheral and axial joint disease, skin and nail psoriasis, enthesitis, and dactylitis, with 72% having moderate-to-high disease activity assessed by cDAPSA. These characteristics are generally consistent with the aforementioned Spanish cohort, although only 48% of those patients had DAPSA moderate-to-high disease activity and a greater proportion (24 vs. 13%) had dactylitis [30].
The current cohort of patients with active PsA and persistent on-label guselkumab use exhibited significant mean improvements from baseline at 6 months in peripheral joint arthritis, pain, and skin disease, as measured by cDAPSA, PGA of arthritis and psoriasis, patient-reported pain, and %BSA; findings were largely consistent with those observed in the sensitivity analysis population of All Persisters. Improvements were also observed in exploratory outcomes evaluating other PsA disease domains, including enthesitis and skin and nail disease, as well as by mean changes in CDAI, an instrument utilized predominantly in clinical practice to assess overall disease activity [22]. Furthermore, 22% of the patients in the primary analysis cohort who did not meet MDA/VLDA criteria at baseline achieved this stringent outcome at 6 months, which is in line with the 15–30% MDA/VLDA response rates observed with 6 months of guselkumab treatment in clinical trials [10,11,12]. Achievement of minimal levels of disease activity is an important outcome [34] that has been shown to be associated with low rates of radiographic progression [35] and long-term improvements in health-related quality of life and functional ability [35, 36]. Specific to guselkumab, results of a recent analysis from the 2-year DISCOVER-2 study, which enrolled bio-naïve patients with active PsA and an elevated risk of future structural damage, showed that patients with active PsA receiving guselkumab who achieved low levels of disease activity (including MDA) generally had lower rates of radiographic progression, on average, than patients who did not achieve these treatment targets [37]. Patients in the real-world Spanish and Italian cohorts who received guselkumab for PsA also realized significant improvements in articular and skin manifestations at 6 months [30, 31].
Although dactylitis was present in a minority of patients at baseline (13%), six of these 12 achieved resolution by 6 months. In the larger DISCOVER-1 (mixed population), DISCOVER-2 (biologic-naïve), and COSMOS (TNFi-IR) trials, 65, 59, and 45% of patients with baseline dactylitis, respectively, achieved resolution with 6 months of guselkumab treatment [10,11,12].
The clinical effectiveness of guselkumab reported herein supports the efficacy demonstrated at the primary endpoint (week 24) in the phase 3, randomized, placebo-controlled trials of guselkumab conducted in biologic-naïve and TNFi-experienced adults with active PsA [10,11,12]. The magnitude of effect size with guselkumab observed in the present study—among patients who were primarily bDMARD-experienced (including TNFi)—is consistent with a separate analysis of PsA patients in the CorEvitas PsA/SpA Registry showing a higher likelihood of achieving clinical outcomes, including MDA, after 6 months of treatment among patients who switched from a first-line TNFi to a non-TNFi than in those who cycled to an alternate TNFi [38].
The real-world setting of the CorEvitas PsA/SpA Registry allows for comprehensive analyses of patient-level data captured by rheumatologists across the US. Additionally, it is noteworthy that in this real-world analysis, the primary and major secondary endpoints were controlled for multiplicity. While the findings of the current analysis may not be generalizable to patients outside the US, participants in this registry may be more representative of the general population of patients with PsA considering biologic therapy than the more homogeneous populations of clinical trials.
As potential limitations, patient selection based on guselkumab persistence at a 6-month follow-up visit (within a 5- to 9-month window) may introduce time and selection biases. While some differences were noted in baseline patient characteristics between All Persisters and Non-Persisters, they should be interpreted with caution due to the small sample size of Non-Persisters and the limited details available regarding end of treatment exposure. Persistence at 6 months was confirmed for patients in the On-Label Persisters cohort; however, a small subset of Non-Persisters who reported stopping guselkumab treatment close to the 6-month visit date may have continued to be exposed to guselkumab at the 6-month follow-up visit. Also, the lack of precision in the reporting of some dates (i.e., month and year only) may have affected the determination of visit windows. Findings derived from exploratory outcomes may also be limited by small sample sizes and lack of multiplicity control in statistical testing. Furthermore, this study focused on the effectiveness of guselkumab assessed via primary, secondary, and composite outcomes with reliance on physician-reported assessments, which may be discordant with patients’ perception of their disease activity [39]. Details of patient-reported outcome measures at guselkumab initiation and after 6 months of treatment will be reported in a forthcoming publication to further assess the effectiveness of guselkumab in reducing disease burden in these patients. While 6 months is an adequate follow-up period to assess initial response to therapy, longer-term evaluations are needed to assess the durability of the effectiveness of guselkumab; as such an evaluation through 12 months of persistent guselkumab use in this patient population is planned. In the interim, it is reassuring that response rates determined using nonresponder imputation among guselkumab-treated patients were sustained or increased through the completion of the 1-year DISCOVER-1 [27] and COSMOS [12] studies and the 2-year DISCOVER-2 study [28, 29].
Although safety data were not prospectively assessed in these analyses, three patients who discontinued guselkumab did so owing to a “minor side effect.” In large, randomized, placebo-controlled studies, guselkumab has been shown to exhibit a positive benefit–risk profile through up to 2 years in patients with active PsA [40, 41], with a safety profile consistent with placebo (through approximately 6 months) and that observed with up to 5 years of guselkumab treatment in patients with moderate-to-severe plaque psoriasis [42].
Conclusions
This is among the first studies to capture real-world guselkumab effectiveness data in patients with generally treatment-resistant active PsA seen in routine clinical practice in the US. Significant improvements in peripheral joint disease, skin disease activity, and patient-reported pain were observed in primarily biologic-experienced patients with 6 months of persistent on-label guselkumab use. These data support the efficacy of guselkumab demonstrated in phase 3, randomized, placebo-controlled trials and offer valuable insights on the effectiveness of guselkumab in the routine care of patients with PsA.
References
Armstrong AW, Mehta MD, Schupp CW, Gondo GC, Bell SJ, Griffiths CEM. Psoriasis prevalence in adults in the United States. JAMA Dermatol. 2021;157:940–6.
Belasco J, Wei N. Psoriatic arthritis: what is happening at the joint? Rheumatol Ther. 2019;6:305–15.
Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79:700–12.
Coates LC, Soriano ER, Corp N, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18:465–79.
Coates LC, Kavanaugh A, Mease PJ, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol. 2016;68:1060–71.
McGagh D, Coates LC. Assessment of the many faces of PsA: single and composite measures in PsA clinical trials. Rheumatology (Oxford). 2020;59:i29–36.
Singh JA, Guyatt G, Ogdie A, et al. Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. Arthritis Rheumatol. 2019;71:5–32.
Tremfya: Package insert. Horsham, PA: Janssen Biotech, Inc.; 2022.
Boehncke WH, Brembilla NC, Nissen MJ. Guselkumab: the first selective IL-23 inhibitor for active psoriatic arthritis in adults. Expert Rev Clin Immunol. 2021;17:5–13.
Deodhar A, Helliwell PS, Boehncke WH, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395:1115–25.
Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395:1126–36.
Coates LC, Gossec L, Theander E, et al. Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS). Ann Rheum Dis. 2022;81:359–69.
Mease PJ, Ogdie A, Chakravarty SD, et al. Clinical characteristics of registry participants with psoriatic arthritis initiating guselkumab: an analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. Drugs Real World Outcomes. 2022;9:617–28.
Cauli A, Gladman DD, Mathieu A, et al. Physician’s Global Assessment in psoriatic arthritis: a multicenter GRAPPA study. J Rheumatol. 2018;45:1256–62.
Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheumatol. 1993;36:729–40.
Kwok T, Pope JE. Minimally important difference for patient-reported outcomes in psoriatic arthritis: Health Assessment Questionnaire and pain, fatigue, and global visual analog scales. J Rheumatol. 2010;37:1024–8.
Mease PJ. Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI). Arthritis Care Res (Hoboken). 2011;63(Suppl 11):S64-85.
Healy PJ, Helliwell PS. Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis. Arthritis Rheumatol. 2008;59:686–91.
Maksymowych WP, Mallon C, Morrow S, et al. Development and validation of the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index. Ann Rheum Dis. 2009;68:948–53.
Langley RGB, Feldman SR, Nyirady J, van de Kerkhof P, Papavassilis C. The 5-point Investigator’s Global Assessment (IGA) Scale: a modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatolog Treat. 2015;26:23–31.
Schoels MM, Aletaha D, Alasti F, Smolen JS. Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis. 2016;75:811–8.
Smolen JS, Aletaha D. Scores for all seasons: SDAI and CDAI. Clin Exp Rheumatol. 2014;32:S-75-9.
Pincus T. A multidimensional health assessment questionnaire (MDHAQ) for all patients with rheumatic diseases to complete at all visits in standard clinical care. Bull NYU Hosp Jt Dis. 2007;65:150–60.
Pincus T, Swearingen CJ, Bergman MJ, et al. RAPID3 (Routine Assessment of Patient Index Data) on an MDHAQ (Multidimensional Health Assessment Questionnaire): agreement with DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) activity categories, scored in five versus more than ninety seconds. Arthritis Care Res (Hoboken). 2010;62:181–9.
Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheumatol. 1980;23:137–45.
Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis. 2010;69:48–53.
Ritchlin CT, Helliwell PS, Boehncke WH, et al. Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naive or TNFα inhibitor-experienced. RMD Open. 2021;7:e001457.
McInnes IB, Rahman P, Gottlieb AB, et al. Efficacy and safety of guselkumab, an interleukin-23p19-specific monoclonal antibody, through one year in biologic-naïve patients with psoriatic arthritis. Arthritis Rheumatol. 2021;73:604–16.
McInnes IB, Rahman P, Gottlieb AB, et al. Long-term efficacy and safety of guselkumab, a monoclonal antibody specific to the p19 subunit of interleukin-23, through two years: results from a phase III, randomized, double-blind, placebo-controlled study conducted in biologic-naive patients with active psoriatic arthritis. Arthritis Rheumatol. 2022;74:475–85.
Rocamora V, Crespi L, Ferran M, et al. Guselkumab effectiveness and survival in patients with psoriasis and psoriatic arthritis: multicenter analysis in daily clinical practice by the Spanish Psoriasis Group. Dermatol Ther. 2022;35:e15865.
Pantano I, Mauro D, Romano F, et al. Real-life efficacy of guselkumab in patients with early psoriatic arthritis. Rheumatology (Oxford). 2022;61:1217–21.
Yiu ZZN, Becher G, Kirby B, et al. Drug survival associated with effectiveness and safety of treatment with guselkumab, ixekizumab, secukinumab, ustekinumab, and adalimumab in patients with psoriasis. JAMA Dermatol. 2022;158:1131–41.
Fitzgerald T, Zhdanava M, Pilon D, et al. Long-term psoriasis control with guselkumab, adalimumab, secukinumab, or ixekizumab in the USA. Dermatol Ther (Heidelb). 2023;13:1053–68.
Coates LC, Helliwell PS. Treating to target in psoriatic arthritis: how to implement in clinical practice. Ann Rheum Dis. 2016;75:640–3.
Kavanaugh A, van der Heijde D, Beutler A, et al. Radiographic progression of patients with psoriatic arthritis who achieve minimal disease activity in response to golimumab therapy: results through 5 years of a randomized, placebo-controlled study. Arthritis Care Res (Hoboken). 2016;68:267–74.
Coates LC, Mease PJ, Gossec L, et al. Minimal disease activity among active psoriatic arthritis patients treated with secukinumab: 2-year results from a multicenter, randomized, double-blind, parallel-group, placebo-controlled phase III study. Arthritis Care Res (Hoboken). 2018;70:1529–35.
Gottlieb AB, McInnes IB, Rahman P, et al. Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naive patients with active psoriatic arthritis. RMD Open. 2023;9:e002789.
Ogdie A, Mclean R, Blachley T, et al. The impact of second-line therapeutic on disease control after discontinuation of first line TNF inhibitor in patients with PsA: analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry [abstract]. Arthritis Rheumatol. 2022;74(suppl 9). https://acrabstracts.org/abstract/the-impact-of-second-line-therapeutic-on-disease-control-after-discontinuation-of-first-line-tnf-inhibitor-in-patients-with-psa-analysis-from-the-corevitas-psoriatic-arthritis-spondyloarthritis-regis/.
Merola JF, Ogdie A, Gottlieb AB, et al. Patient and physician perceptions of psoriatic disease in the United States: results from the UPLIFT survey. Dermatol Ther (Heidelb). 2023:1–18.
Rahman P, Boehncke WH, Mease PJ, et al. Safety of guselkumab with and without prior tumor necrosis factor inhibitor treatment: pooled results across 4 studies in patients with psoriatic arthritis. J Rheumatol. 2023. https://doi.org/10.3899/jrheum.220928.
Rahman P, Ritchlin CT, Helliwell PS, et al. Pooled safety results through 1 year of 2 phase III trials of guselkumab in patients with psoriatic arthritis. J Rheumatol. 2021;48:1815–23.
Blauvelt A, Tsai TF, Langley RG, et al. Consistent safety profile with up to 5 years of continuous treatment with guselkumab: pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis. J Am Acad Dermatol. 2022;86:827–34.
Acknowledgements
Funding
This study is sponsored by CorEvitas, LLC, and the analysis was funded by Janssen Scientific Affairs, LLC. Medical writing assistance and the journal’s Rapid Service Fee were funded by Janssen Scientific Affairs, LLC. Access to study data was limited to CorEvitas; CorEvitas statisticians completed all analyses, and all authors contributed to the interpretation of the results. CorEvitas has been supported through contracted subscriptions in the last 2 years by AbbVie, Amgen, Inc., Arena, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Chugai, Eli Lilly and Company, Genentech, Gilead Sciences, Inc., GlaxoSmithKline, Janssen Pharmaceuticals, Inc., LEO Pharma, Novartis, Ortho Dermatologics, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Sanofi, Sun Pharmaceutical Industries Ltd., and UCB S.A.
Medical Writing, Editorial, and Other Assistance
Medical writing and editorial support was provided by Rebecca Clemente, PhD, and Michelle L. Perate, MS, (both employees of Janssen Scientific Affairs, LLC), under the direction of the authors in accordance with Good Publication Practice guidelines (Ann Intern Med 2022;175:1298–1304).
Authorship
All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for their contribution this article, take responsibility for the integrity of the work as a whole, and approved the manuscript for submission.
Author Contributions
Study design: Philip J Mease, Alexis Ogdie, John Tesser, Natalie J Shiff, Iris Lin, Soumya D Chakravarty, Aaron Broadwell, Arthur Kavanaugh, Joseph F Merola; Data acquisition/analysis: Michael Kelleman, Rhiannon Dodge, Robert R McLean. Data interpretation: Philip J Mease, Alexis Ogdie, John Tesser, Natalie J Shiff, Iris Lin, Soumya D Chakravarty, Michael Kelleman, Rhiannon Dodge, Robert R McLean, Aaron Broadwell, Arthur Kavanaugh, Joseph F Merola. Drafting/revising the manuscript and approval for submission: Philip J Mease, Alexis Ogdie, John Tesser, Natalie J Shiff, Iris Lin, Soumya D Chakravarty, Michael Kelleman, Rhiannon Dodge, Robert R McLean, Aaron Broadwell, Arthur Kavanaugh, Joseph F Merola.
Disclosures
Philip J Mease has received research support, consulting fees, and/or speaker bureau support from AbbVie, Acelyrin, Aclaris, Amgen, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, Inmagene, Janssen, Moonlake Pharma, Novartis, Pfizer, SUN Pharma, UCB, Ventyx, and Xinthera. Alexis Ogdie has received grant/research support to the University of Pennsylvania from AbbVie, Janssen, Novartis, and Pfizer and to Forward from Amgen; consultant fees from AbbVie, Amgen, Bristol Myers Squibb, Celgene, CorEvitas, Eli Lilly, Gilead, Happify Health, Janssen, Novartis, Pfizer, and UCB; her husband has received royalties from Novartis. John Tesser has received grant/research support from AbbVie, Alpine, Amgen, Anthrosi Therapeutics, Bendcare, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, CorEvitas, CSL Behring, DRL, Eli Lilly, Emerald, Exagen, Genentech, Gilead, Global Health Living Foundation, Horizon, Janssen, Kolon TissueGene, Mitsubishi, Organogenesis, Pfizer, Samumed/Biosplice, Selecta, Setpoint, Sun Pharma, Takeda, and Vorso; served on advisory boards or as a consultant for AbbVie, Amgen, AstraZeneca, Aurinia, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly, GlaxoSmithKline, Janssen, Novartis, Pfizer, Samumed/Biosplice, Sanofi-Genzyme, and UCB; speaker fees from AbbVie, Amgen, Aurinia, AstraZeneca, Bristol Myers Squibb (through 2021), Eli Lilly, GlaxoSmithKline, Janssen, Pfizer, and Sanofi/Genzyme. Natalie J. Shiff is an employee of Janssen Scientific Affairs, LLC; received salary support from the Childhood Arthritis and Rheumatology Research Alliance within the past 3 years; owns or has owned within the past 3 years stock in AbbVie, Gilead, Iovance, Jazz Pharmaceuticals, Johnson & Johnson, Novo-Nordisc, Novavax, Pfizer, and Viatris. Iris Lin, Soumya D. Chakravarty are employees of Janssen Scientific Affairs, LLC and own stock or stock options in Johnson & Johnson. Michael Kelleman, Rhiannon Dodge, Robert R. McLean are employees of CorEvitas, LLC. Aaron Broadwell has received consulting fees from AbbVie, Amgen, Aurinia, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, and Sandoz; speaker fees from AbbVie, Amgen, Eli Lilly, Horizon, Janssen, Mallinckrodt, Novartis, Pfizer, Radius, Sanofi/Regeneron, and UCB. Arthur Kavanaugh has received consulting fees from AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Janssen, Merck, Novartis, Pfizer, and UCB. Joseph F. Merola has received consulting fees and investigator honoraria from AbbVie, Amgen, Biogen, Bristol Myers Squibb, Dermavant, Eli Lilly, Incyte, Janssen, Leo Pharma, Novartis, Pfizer, Regeneron, Sanofi, Sun Pharma, and UCB.
Compliance with Ethics Guidelines
This study was performed in accordance with the Declaration of Helsinki and the Guidelines for Good Pharmacoepidemiology Practice. All participating investigators were required to obtain full governing board approval for conducting noninterventional research involving humans with a limited dataset. Sponsor approval and continuing review were obtained through a central Institutional Review Board (IRB), the New England Independent Review Board (no. 120160939). For academic investigative sites that did not receive authorization to use the central IRB, full board approval was obtained from their respective governing IRBs, and documentation of approval was submitted to CorEvitas, LLC before the site’s participation and initiation of any study procedures. All patients provided written informed consent and authorization before participating.
Data Availability
Data are available from CorEvitas, LLC through a commercial subscription agreement and are not publicly available. No additional data are available from the authors.
Author information
Authors and Affiliations
Corresponding author
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
Mease, P.J., Ogdie, A., Tesser, J. et al. Six-Month Persistence and Multi-domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. Rheumatol Ther 10, 1479–1501 (2023). https://doi.org/10.1007/s40744-023-00582-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40744-023-00582-w